Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jul;69(3):747-8.
doi: 10.1007/s12013-014-9833-7.

Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis

George Imataka  1 , Osamu Arisaka
Affiliations
Case Reports

Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis

George Imataka et al. Cell Biochem Biophys. 2014 Jul.

Abstract

Juvenile dermatomyositis (JDM) is a multisystem disease characterized by non-purulent inflammation in the striated muscle and skin. Banker-type JDM is difficult to treat and control, especially when it is a form that is resistant to steroid treatment. Here, we report a 2-year-old girl with Banker-type JDM resistant to steroid treatment. The patient received intravenous immunoglobulin (IVIg) at 400 mg/kg/5 days a week every 6 weeks. Motor function improved and the patient was able to walk after six cycles. IVIg was administered every four weeks for six cycles thereafter, and the patient was able to walk more quickly with an improvement in quality of life. No apparent adverse effects were observed during IVIg treatment.

PubMed Disclaimer

References

    1. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nature Reviews Rheumatology. 2011;7:664–675. doi: 10.1038/nrrheum.2011.139. - DOI - PubMed
    1. Amano H, Nagai Y, Katada K, Hashimoto C, Ishikawa O. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. The British journal of dermatology. 2007;156:1390–1392. doi: 10.1111/j.1365-2133.2007.07891.x. - DOI - PubMed
    1. Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Annals of the Rheumatic Diseases. 2011;70:2089–2094. doi: 10.1136/ard.2011.153718. - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources